Targeting and killing glioblastoma with monoclonal antibody to O-acetyl GD2 ganglioside.

Abstract

There are still unmet medical needs in the treatment of glioblastoma, the most common and the most aggressive glioma of all brain tumors. Here, we found that O-acetyl GD2 is expressed in surgically resected human glioblastoma tissue. In addition, we demonstrated that 8B6 monoclonal antibody specific for O-acetylat GD2 could effectively inhibit glioblastoma cell proliferation in vitro and in vivo. Taken together, these results indicate that O-acetylated GD2 represents a novel antigen for immunotherapeutic-based treatment of high-grade gliomas.

• Authors: Julien Fleurence, Denis Cochonneau, Sophie Fougeray, Lisa Oliver, Fanny Geraldo, Mickaël Terme, Mylène Dorvillius, Delphine Loussouarn, François Vallette, François Paris, Stéphane Birklé
• Journal: Oncotarget (Oncotarget) Vol. 7 Issue 27 Pg. 41172-41185 (Jul 05 2016) ISSN: 1949-2553 [Electronic] United States
• PMID: 27172791 (Publication Type: Journal Article)

Chemical References

• Antibodies, Monoclonal
• Cancer Vaccines
• Gangliosides
• ganglioside, GD2

Topics

• Adult
• Aged
• Animals
• Antibodies, Monoclonal (therapeutic use)
• Apoptosis (immunology)
• Cancer Vaccines (therapeutic use)
• Cell Line, Tumor
• Female
• Gangliosides (immunology, metabolism)
• Glioblastoma (immunology, metabolism, therapy)
• Humans
• Male
• Mice
• Mice, Inbred BALB C
• Mice, Nude
• Middle Aged
• Molecular Targeted Therapy (methods)
• Xenograft Model Antitumor Assays